Table 1 Tumoral and tumor-associated immune TIM-3 expression by mismatch repair status, n/N (%)

From: TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers

 

+TIM-3 (≥1%) in tumor cells

+TIM-3 in TAIs

TIM-3 CPS ≥1

MMR deficient

(N = 50)

40/50 (80%)

50/50 (100%)

50/50 (100%)

nm-MMRd

(N = 25)

19/25 (76%)

25/25 (100%)

25/25 (100%)

 

Extent of expression:

Extent of expression:

 
 

1–5%:11/25 (44%)

Focal: 10/25 (40%)

 
 

6–10%:5/25 (20%)

Moderate: 8/25 (32%)

 
 

11–25%:0/25 (0%)

Robust: 7/25 (28%)

 
 

26–50%:1/25 (4%)

  
 

>50%:2/25 (8%)

  

MLH1-hm

(N = 25)

21/25 (84%)

25/25 (100%)

25/25 (100%)

 

Extent of expression:

Extent of expression:

 
 

1–5%: 5/25 (20%)

Focal: 7/25 (28%)

 
 

6–10%:8/25 (32%)

Moderate: 14/25 (56%)

 
 

11–25%:4/25 (16%)

Robust: 4/25 (16%)

 
 

26–50%:3/25 (12%)

  
 

>50%:1/25 (4%)

  

MMR intact

(N = 25)

18/25 (72%)

25/25 (100%)

25/25 (100%)

 

Extent of expression:

Extent of expression:

 
 

1–5%:11/25 (44%)

Focal: 22/25 (88%)

 
 

6–10%:2/25 (8%)

Moderate: 3/25 (12%)

 
 

11–25%:2/25 (8%)

Robust: 0/25 (0%)

 
 

26–50%:1/25 (4%)

  
 

>50%:2/25 (8%)

  
  1. TAI tumor-associated immune, CPS combined positive score, MMR mismatch repair, MMRd mismatch repair-deficient, hm hypermethylated, nm non-methylated
Back to article page